(rivaroxaban)
This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
XARELTO® (rivaroxaban)
Medical Information
XARELTO - Reversal Agents in Human Studies - Other - Tranexamic Acid
Last updated : 05/16/2024
Clave et al (2012) assessed the efficacy of tranexamic acid in reducing blood loss during primary cementless THR in patients using XARELTO alone for thromboprophylaxis in a single-blind, prospective, case-control study.1
Study Design1
Study Assessments
- To assess tranexamic acid action, pre- and postoperative blood effusion volume; real blood loss; need for PRBC transfusion; hemoglobinemia at day 0 (preoperative), day 1, and day 5; and complications were systematically collected.1
- Twelve patients on antiplatelet therapy (6 in group A and 6 in group B) had therapy interrupted 5 days before surgery and resumed 1 day after surgery.1
- In group A, no PRBC transfusions were needed; in group B, there were 4 transfusions.
- No thromboembolic complications were observed at discharge or at 3-month follow-up.
- Blood loss and mean hemoglobinemia between groups are provided in the table below.1
Blood Loss and Mean Hemoglobinemia1
|
Group A: Tranexamic acid |
Group B: Control |
P-value |
|
|---|---|---|---|
|
Mean peroperative blood effusion volume, mL |
227.0 |
229.8 |
0.9529 |
|
Mean postoperative blood loss, mL |
440.5 |
641.8 |
0.0002 |
|
Mean real blood loss, mL of 100% hematocrit |
414.6 |
587.6 |
0.0006 |
Mean hemoglobinemia, g/dL |
|||
|
Day 0 |
14.15 |
14.14 |
0.471 |
|
Day 1 |
11.41 |
10.51 |
0.002 |
|
Day 5 |
11.05 |
10.24 |
0.002 |
IV, intravenous; PRBC, packed red blood cell; THR, total hip replacement.
Reference
Show Hide
1. Clave A, Fazilleau F, Dumser D, et al. Efficacy of tranexamic acid on blood loss after primary cementless total hip replacement with rivaroxaban thromboprophylaxis: a case-control study in 70 patients. Orthop Traumatol Surg Res. 2012;98(5):484-490.
